Duration of treatment.

The time to discontinuation of study drug was shorter for patients who received thalidomide than for those who received placebo. One patient who received thalidomide and 5 patients who received placebo continued treatment with study drug until the onset of their terminal illness. These patients were categorized as not having discontinued treatment with the study drug before death.